Orasure Tech Stock Price, News & Analysis

OraSure Technologies (NASDAQ: OSUR) has launched the first commercially available device for in-home self-collection of fecal samples for metabolomics, named OMNImet™·GUT (ME-200). This device, developed by OraSure’s DNA Genotek subsidiary, aims to enhance the study of metabolites important for understanding human health and various diseases. The OMNImet™·GUT allows for sample stability at room temperature for up to seven days, facilitating ease of use for researchers. The product validates a growing trend toward multiomic approaches in life sciences, integrating various biological data for comprehensive health insights.

Metabolon and DNA Genotek, a subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), have launched OMNImet·GUT, a pioneering device designed for in-home collection and ambient-temperature storage of fecal samples for metabolomics research. This collaboration addresses the industry's need for a validated solution that eliminates the complexities of cold chain logistics in sample handling. The device maintains sample integrity, facilitating clinical trials and research in microbiome studies, thus enhancing the understanding of health and disease.

OraSure Technologies (NASDAQ: OSUR) secured a $629,217 contract from BARDA to develop an ELISA for detecting anti-SARS-CoV-2 antibodies in oral fluid. This funding supports the completion of development and filing for FDA Emergency Use Authorization. The oral fluid test aims to enhance laboratory testing capacity, identify past COVID-19 infections, and support workforce reintegration. The test can collect samples painlessly and may be adapted for home use, promoting social distancing. Initial product sales are targeted for this summer pending successful development.

OraSure Technologies (Nasdaq: OSUR) announced the full exercise of underwriters' option to purchase an additional 1,200,000 shares in its stock offering, increasing the total to 9,200,000 shares. This move is expected to generate approximately $94.9 million in net proceeds after discounts and fees, with the offering closing on June 5, 2020. The funds will be used to expand manufacturing for COVID-19 testing and to explore potential acquisitions. The offering is compliant with SEC regulations, with management highlighting its strategic importance.

OraSure Technologies (Nasdaq: OSUR) has priced an underwritten public offering of 8,000,000 shares of common stock at $11.00 per share, expecting net proceeds of approximately $82.48 million. The offering will close on June 5, 2020, subject to customary conditions. The company intends to use the funds to expand manufacturing for COVID-19 testing products, pursue acquisitions, and cover general corporate expenses. An additional 1,200,000 shares may be purchased by underwriters within 30 days.

OraSure Technologies (Nasdaq: OSUR) announced an underwritten public offering of 8,000,000 shares of its common stock, with a potential additional 1,200,000 shares available to underwriters. The proceeds will be used to expand manufacturing for COVID-19 testing products, fund acquisitions, and support general corporate uses. The company’s ability to complete the offering is subject to market conditions. J.P. Morgan, Citigroup, and Evercore are the lead underwriters for this offering.

OraSure Technologies, a leader in point of care diagnostics, announced that Dr. Stephen S. Tang, Ph.D., President and CEO, will present at the Jefferies 2020 Healthcare Conference on June 2, 2020, at 3:00 PM EST. The event will be available for live streaming on OraSure's website, and a replay will be accessible for seven days post-event. OraSure Technologies focuses on providing accurate health information and offers a range of diagnostic products and services globally, aimed at improving health and wellness.

OraSure Technologies (NASDAQ: OSUR) announced that its OMNIgene®·ORAL saliva collection device (OM-505) received FDA Emergency Use Authorization (EUA) for at-home SARS-CoV-2 testing by P23 Labs. This device allows self-collection of saliva samples, enhancing testing accessibility for individuals unable to visit collection centers. This marks the second EUA for a DNA Genotek collection device, following the ORAcollect®·RNA kit’s EUA earlier in May. OraSure aims to boost COVID-19 testing while reducing infection risks and PPE demands.

Diversigen, a subsidiary of OraSure Technologies (NASDAQ: OSUR), has been selected by Nom Nom™, a pet health brand, as their preferred provider for microbiome sequencing and analysis services. This partnership aims to enhance pet health through personalized nutrition informed by microbiome data. Nom Nom has conducted significant research on pet gut health, including a major study analyzing 238 pets. Diversigen's expertise in metagenomics and bioinformatics will support this initiative, utilizing advanced sequencing solutions to deepen the understanding of pet health issues linked to the microbiome.